CombiGene
Lund, Skane Lan, Sweden
About CombiGene
CombiGene provides patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. CombiGene is developing a breakthrough therapy with the potential to dramatically improve the quality of life for a group of epilepsy patients for whom there is currently no effective treatment. CombiGene uses an adeno-associated viral vector (AAV) to administer a combination of neuropeptide Y (NPY) and its receptor Y2 directly to the part of the brain where the epileptic seizure begins. The most important preclinical effect studies have been concluded with positive results and the next step will be the compulsory safety studies. Given a positive outcome from the safety studies and successful GMP production of CG01, studies in humans can begin.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $3.9M
- Funding stage: IPO
- Last round: Post-IPO Equity (Feb 2024)
- Ticker: sto:COMBI
- Website: combigene.com
Industries & Categories
Biotechnology, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/combigene-2253516 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.